Sign In
Buy IBIO
$1.84
+0.0800 (+4.55%)
At Close: Jun 03, 2026
Why iBio Presents a Dilemma to Shareholders
02:41pm, Friday, 20'th Nov 2020
iBio's first-quarter included steep losses and not much else. If IBIO stock is to rise to $2, investors need some good news to chew on.
Stay Away From iBio, Which Constantly Issues Shares to Survive
10:13am, Friday, 20'th Nov 2020
The latest in IBIO news: stay away from IBIO stock, which has over-issued shares to survive. The stock remains below the average issue price.
iBio, Inc. (iBio) CEO Thomas Isett on Q1 2021 Results - Earnings Call Transcript
10:44pm, Monday, 16'th Nov 2020
iBio, Inc. (iBio) CEO Thomas Isett on Q1 2021 Results - Earnings Call Transcript
iBio Reports Fiscal First Quarter 2021 Financial Results and Provides Corporate Update
04:05pm, Monday, 16'th Nov 2020
BRYAN, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, today announced its fi
Up 600% Year-to-Date, Sell iBio Stock While It's Still Flying High
10:48am, Friday, 13'th Nov 2020
The latest iBio news isn't good. It's taken too long for IBIO to develop a coronavirus vaccine and now the opportunity has disappeared.
Two Covid-19 Vaccine Candidates Hold Promise for iBio
04:34pm, Wednesday, 11'th Nov 2020
iBio has a huge vertical farming facility and a couple of high-potential vaccine candidates, which should offer hope to IBIO stock holders. The post Two Covid-19 Vaccine Candidates Hold Promise for iB
iBio Remains a Biotech Sideline Play as Covid Rages
02:12pm, Monday, 09'th Nov 2020
Investor interest a unique production system isn't enough to make buying IBIO stock a worthwhile move at this time. The post iBio Remains a Biotech Sideline Play as Covid Rages appeared first on Inves
iBio to Report Fiscal 2021 First Quarter Financial Results and Provide Corporate Update on Monday, November 16 ,2020
04:30pm, Thursday, 05'th Nov 2020
BRYAN, Texas, Nov. 05, 2020 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a biotech innovator and biologics contract manufacturing organization, announced today that i
First to COVID-19 Vaccine or Not, iBio Is a Smart Investment
11:35am, Wednesday, 04'th Nov 2020
IBIO stock has been hit hard by its apparent failure to produce the first COVID-19 vaccine, but that's a simplistic view of iBio's prospects. The post First to COVID-19 Vaccine or Not, iBio Is a Smart
iBio Announces Appointment of Randy J. Maddux as Chief Operating Officer
07:30am, Tuesday, 03'rd Nov 2020
- Brings >20 Years of Global Biotech Operations and Business Development Experience - - Brings >20 Years of Global Biotech Operations and Business Development Experience -
IBIO Stock Remains a Speculative Biopharma Play
07:53am, Thursday, 29'th Oct 2020
Yes, I will continue to root for Ibio in its fight to make a huge leap with its Covid-19 efforts. But where my investment dollar is concerned, it'll be from the sidelines.
Is It Too Late to Buy iBio Stock?
06:29am, Thursday, 29'th Oct 2020
The time to make money by investing in iBio is over. Here's why that's good news.
Disappointing iBio Is Too Far Behind to Make an Impact
12:24pm, Wednesday, 14'th Oct 2020
What was once a promising investment in IBIO stock has turned into an untenable case as setbacks mount higher.
iBio: Slow On COVID-19 Clinical Progress, A Viable Short Candidate (NYSEMKT:IBIO)
07:04pm, Wednesday, 07'th Oct 2020
A recent 10-Q for IBIO mentions the word plasma just once. IBIO isn't a plasma company like ADMA and isn't developing a plasma-derived product for COVID-19 like KMDA.
It's Hard to Trust iBio When It's Lagging the Competition
12:05pm, Wednesday, 23'rd Sep 2020
Not only that IBIO stock has suffered because the underlying company's prior candidates have failed to materialize.
